SMARCA4 and non-small cell lung carcinoma: There were 44 NSCLC patients with SMARCA4 mutations, and men (N = 25) had a significantly worse OS than women (N = 19) (2.75 months vs. inestimable, HR:14.2; p = 0.02) [26].